Immunobiological markers of the effectiveness of antipsychotic therapy in patients with schizophrenia

Immunobiological markers of the effectiveness of antipsychotic therapy in patients with schizophrenia

 

Authors

 

O.A. Lobacheva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

V.B. Nikitina

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

E.V. Gutkevich

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation;Federal State Autonomous Educational Institution of Higher Education “National Research Tomsk State University”, Tomsk, Russian Federation

A.E. Pershina

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

T.V. Pogorelova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

T.V. Kazennykh

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

E.G. Kornetova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-4(129)-5-12

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 4 (129):  5-12.

 

Abstract

Background. Immunoinflammation plays a significant role in the pathogenesis of schizophrenia. The immunomodulatory and anti-inflammatory effects of antipsychotics support the role of inflammation in schizophrenia. However, the effects of individual psychotropic medications on the immune system and how this may contribute to their effectiveness remain largely unclear. Proinflammatory and anti-inflammatory cytokines and acute-phase proteins can be used as markers of inflammation in schizophrenia. Predicting individual response to therapy before initiating treatment with atypical antipsychotics is a pressing issue in practical medicine. Objective: to identify immunobiological markers for predicting the effectiveness of antipsychotic therapy in patients with schizophrenia. Materials and Methods. A clinical, psychopathological and immunobiological examination of 40 patients with schizophrenia (F20.00, F20.01, F20.02, F20.3, F20.6 according to ICD-10) aged 20-64 years was conducted. Based on the results of assessing the dynamics of improvement in the state during treatment using the Clinical Global Impression (CGI) scale, two groups were formed: Group 1 (n=32) ‒ with a significant improvement in mental state, Group 2 (n=8) ‒ with an insignificant improvement in mental state. Laboratory testing included determination of the concentration of cytokines interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP) in the blood serum of patients using enzyme-linked immunosorbent assay. The findings were analyzed using statistical methods. Results. It was shown that patients with schizophrenia at point 1 of the study had higher median levels of IL-6 and TNF-α compared to healthy individuals. The most pronounced features of group 1 of patients (with a significant improvement in mental state) compared to group 2 (with insignificant improvement) before the administration of antipsychotic therapy were statistically significantly higher levels of TNF-α (p=0.0006) and CRP (p=0.0156), as well as lower IL-6 values (p=0.0069). These immunity indicators can be considered as markers for predicting the effectiveness of therapy for patients with schizophrenia. Conclusion. New data on the role of inflammatory markers in the pathogenetic mechanisms of schizophrenia have been obtained, allowing for targeted rehabilitation psychopharmacological measures.

 

Keywords: schizophrenia, antipsychotic therapy efficacy, proinflammatory cytokines, C-reactive protein.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Lobacheva O.A., Nikitina V.B., Gutkevich E.V., Pershina A.E., Pogorelova T.V., Kazennykh T.V., Kornetova E.G. Immunobiological markers of the effectiveness of antipsychotic therapy in patients with schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry.2025; 4 (129): 5-12. https://doi.org/10.26617/1810-3111-2025-4(129)-5-12

 

REFERENCES

  1. Marques TR, Ashok AH, Pillinger T, Veronese M, Turkheimer FE, Dazzan P, Sommer IEC, Howes OD. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med. 2019 Oct;49(13):2186-2196. https://doi.org/10.1017/S0033291718003057. Epub 2018 Oct 25. PMID: 30355368; PMCID: PMC6366560.
  2. van Kesteren CF, Gremmels H, de Witte LD, Hol EM, Van Gool AR, Falkai PG, Kahn RS, Sommer IE. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiatry. 2017 Mar 28;7(3):e1075. https://doi.org/10.1038/tp.2017.4. PMID: 28350400; PMCID: PMC5404615.
  3. Zozulya SA, Sarmanova ZV, Otman IN, Klyushnik TP. Inflammatory markers in schizophrenia for science and practice. Doctor.Ru. 2023; 22(6):7-14. https://doi.org/10.31550/1727-2378-2023-22-6-7-14(in Russian).
  4. Sobiś J, Rykaczewska-Czerwińska M, Świętochowska E, Gorczyca P. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity.Pharmacol Rep. 2015 Apr;67(2):353-9.https://doi.org/10.1016/j.pharep.2014.09.007. Epub 2014 Sep 26. PMID: 25712663.
  5. Yogaratnam J, Biswas N, Vadivel R, Jacob R. Metabolic complications of schizophrenia and antipsychotic medications ‒ an updated review. East Asian Arch Psychiatry. 2013 Mar;23(1):21-8. PMID: 23535629.
  6. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl). 2016 May;233(9):1575-89.https://doi.org/10.1007/s00213-015-4044-5. Epub 2015 Aug 14. PMID: 26268146.
  7. Malashenkova IK, Krynsky SA, Ogurtsov DP, Mamoshina MV, Zakharova NV, Ushakov VL, Velichkovsky BM, Didkovsky NA. A role of the immune system in the pathogenesis of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):72-80. https://doi.org/10.17116/jnevro201811812172(in Russian).
  8. Romeo B, Brunet-Lecomte M, Martelli C, Benyamina A. Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: A meta-analysis. Int J Neuropsychopharmacol. 2018 Sep 1;21(9):828-836. https://doi.org/10.1093/ijnp/pyy062. PMID: 30016466; PMCID: PMC6119290.
  9. Mednova IA, Boiko AS, Kornetova EG, Semke AV, Bokhan NA, Ivanova SA. Cytokines as potential biomarkers of clinical characteristics of schizophrenia. Life (Basel). 2022 Nov 25;12(12):1972. https://doi.org/10.3390/life12121972. PMID: 36556337; PMCID: PMC9784438.
  10. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007 Dec;65(12 Pt 2):S140-6. https://doi.org/10.1111/j.1753-4887.2007.tb00352.x.PMID: 18240538.
  11. Browning LM, Krebs JD, Jebb SA. Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease. Metabolism. 2004 Jul;53(7):899-903. https://doi.org/10.1016/j.metabol.2004.01.013. PMID: 15254884.
  12. Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of Inflammation. Methods Mol Biol. 2018;1803:57-79. https://doi.org/10.1007/978-1-4939-8549-4_5. PMID: 29882133.
  13. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003 Jun;24(3):278-301. https://doi.org/10.1210/er.2002-0010. PMID: 12788800.
  14. Kim HJ, Higashimor T.I, Park SY, Choi H, Dong J, Kim Y-J, Noh H-L, Cho Y-R, Cline G, Kim Y-B, Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004; 53(4):1060-1067.https://doi.org/10.2337/diabetes.53.4.1060.
  15. Kasprzak A., Seide J, Spachacz R, Biczysko W, Małkowska A, Kaczmarek E, Zabel M. Intracellular expression of proinflammatory cytokines (IL-1 alpha, TNF-alpha, and IL-6) in chronic hepatitis. Rocz Akad Med Bialymst. 2004;49(2):207-209.http://www.advms.pl/roczniki_2004_sup_1/69.pdf
  16. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology. 2008 Sep;48(3):770-81. https://doi.org/10.1002/hep.22423. PMID: 18752326.
  17. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006 Mar;17(1):4-12. PMID: 16613757.
  18. Lee YS, Chung S, Lee YN, Kwon YS, Kim DH, Kim CE, Oh KS, Yeon YW, Lee MS, Lim MH, Chang HR, Kim CE. Efficacy and tolerability of aripiprazole: a 26-week switch-over study from oral antipsychotic therapy. Social and Clinical Psychiatry.2014;24(1):49-52 (in Russian).
  19. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016 Jun;10(3):193-202. https://doi.org/10.1111/eip.12251. Epub 2015 May 12. PMID: 25962699; PMCID: PMC5589463.
  20. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011 Oct 1;70(7):663-71. https://doi.org/10.1016/j.biopsych.2011.04.013. Epub 2011 Jun 8. PMID: 21641581; PMCID: PMC4071300.
  21. Lasić D, Bevanda M, Bošnjak N, Uglešić B, Glavina T, Franić T. Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder. Psychiatr Danub. 2014 Sep;26(3):214-9. PMID: 25191767.
  22. Kelly CW, McEvoy JP, Miller BJ. Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res. 2019 Jul;209:193-197. https://doi.org/10.1016/j.schres.2019.04.021. Epub 2019 May 19. PMID: 31118157.
  23. Pandurangi AK, Buckley PF. Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Curr Top Behav Neurosci. 2020;44:227-244. https://doi.org/10.1007/7854_2019_91. PMID: 30993585.
  24. Lobacheva OA, Vetlugina TP, Semke AV, Evseev SV. Applicant and patent holder: State Institution Research Institute of Mental Health, Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Sciences (RU). A method for predicting the effectiveness of treating patients with schizophrenia with the atypical antipsychotic quetiapine (Seroquel). Russian Federation Patent No. 2289137. IPC G01N. No. 2005114074. Claimed 11.05.2005. Published 10.12.2006. Bulletin No. 36 (in Russian).
  25. Sekirina TP, Kaleda VG. Dynamics of interleukin-10 and gamma-interferon production in patients with the first attack of juvenile endogenous psychosis. Psychiatry. 2009;2:38-42 (in Russian).
  26. Mori N, McEvoy JP, Miller BJ. Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res. 2015 Dec;169(1-3):30-35. https://doi.org/10.1016/j.schres.2015.10.001.Epub 2015 Oct 21. PMID: 26475215.
  27. Hong J, Bang M. Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing. Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):10-24. https://doi.org/10.9758/cpn.2020.18.1.10. PMID: 31958901; PMCID: PMC7006977.